Tripping outside the lines: lessons from observational studies of combination psychedelic use beyond regulated clinical contexts

References

• Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, Ot’alora G M, Garas W, Paleos C, Gorman I, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Focus. 2023;21:315–28. doi:10.1176/appi.focus.23021011.
   PubMedGoogle Scholar
• Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, Finan PH, Griffiths RR. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021;78:481–89. doi:10.1001/jamapsychiatry.2020.3285.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384:1402–11.
   PubMed Web of Science ®Google Scholar
• Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, Bird C, Blom RE, Brennan C, Brusch D, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387:1637–48.
   PubMed Web of Science ®Google Scholar
• Grabski M, McAndrew A, Lawn W, Marsh B, Raymen L, Stevens T, Hardy L, Warren F, Bloomfield M, Borissova A, et al. Adjunctive ketamine with relapse prevention–based psychological therapy in the treatment of alcohol use disorder. Am J Psychiatry. 2022;179:152–62.
   PubMed Web of Science ®Google Scholar
• Peck SK, Shao S, Gruen T, Yang K, Babakanian A, Trim J, Finn DM, Kaye WH. Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. Nat Med. 2023;1–7. doi:10.1038/s41591-023-02455-9.
   PubMed Web of Science ®Google Scholar
• Heifets BD, Olson DE. Therapeutic mechanisms of psychedelics and entactogens. Neuropsychopharmacology. 2023;1–15. doi:10.1038/s41386-023-01666-5.
   PubMed Web of Science ®Google Scholar
• Moghaddam BK. The MIT Press. 2021. doi:10.7551/mitpress/13258.001.0001.
   Google Scholar
• Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351–54. doi:10.1016/S0006-3223(99)00230-9.
   PubMed Web of Science ®Google Scholar
• Artin H, Bentley S, Mehaffey E, Liu FX, Sojourner K, Bismark AW, Printz D, Lee EE, Martis B, De Peralta S, et al. Effects of intranasal (S)-ketamine on veterans with co-morbid treatment-resistant depression and PTSD: a retrospective case series. EClinical Med. 2022;48:101439.
   PubMedGoogle Scholar
• Bentley S, Artin H, Mehaffey E, Liu F, Sojourner K, Bismark A, Printz D, Lee EE, Martis B, De Peralta S, et al. Response to intravenous racemic ketamine after switch from intranasal (S)‐ketamine on symptoms of treatment‐resistant depression and post‐traumatic stress disorder in veterans: a retrospective case series. Pharmacotherapy. 2022;42:272–79. doi:10.1002/phar.2664.
   PubMed Web of Science ®Google Scholar
• Charney D. Ketamine as a rapid treatment for post-traumatic stress disorder. Mount Sinai school of medicine New York, 2009.
   Google Scholar
• Lipov E, Sethi Z, Nandra G, Frueh C. Efficacy of combined subanesthetic ketamine infusion and cervical sympathetic blockade as a symptomatic treatment of PTSD/TBI in a special forces patient with a 1-year follow-up: A case report. Heliyon. 2023;9:e14891. doi:10.1016/j.heliyon.2023.e14891.
   PubMed Web of Science ®Google Scholar
• Ross C, Jain R, Bonnett CJ, Wolfson P. High-dose ketamine infusion for the treatment of posttraumatic stress disorder in combat veterans. Ann Clin Psychiatry. 2019;31:271–79.
   PubMed Web of Science ®Google Scholar
• Shiroma PR, Thuras P, Wels J, Erbes C, Kehle-Forbes S, Polusny M. A proof-of-concept study of subanesthetic intravenous ketamine combined with prolonged exposure therapy among veterans with posttraumatic stress disorder. J Clin Psychiatry. 2020;81:10118. doi:10.4088/JCP.20l13406.
   Web of Science ®Google Scholar
• Mithoefer MC, Feduccia AA, Jerome L, Mithoefer A, Wagner M, Walsh Z, Hamilton S, Yazar-Klosinski B, Emerson A, Doblin R, et al. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology. 2019;236:2735–45. doi:10.1007/s00213-019-05249-5.
   PubMed Web of Science ®Google Scholar
• Mithoefer MC, Mithoefer AT, Feduccia AA, Jerome L, Wagner M, Wymer J, Holland J, Hamilton S, Yazar-Klosinski B, Emerson A, et al. 3, 4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry. 2018;5:486–97.
   PubMed Web of Science ®Google Scholar
• Smith F, Neill J, Wainwright V. An interpretative phenomenological analysis of the use of psilocybin by veterans with symptoms of trauma. Drug Sci, Policy Law. 2022;8:20503245221124117. doi:10.1177/20503245221124117.
   Google Scholar
• Feduccia AA, Jerome L, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R. Breakthrough for trauma treatment: safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline. Front Psychiatry. 2019;10:650. doi:10.3389/fpsyt.2019.00650.
   PubMed Web of Science ®Google Scholar
• Reardon S. US could soon approve MDMA therapy—opening an era of psychedelic medicine. Nature. 2023;616:428–30. doi:10.1038/d41586-023-01296-3.
   PubMedGoogle Scholar
• Siegel JS, Daily JE, Perry DA, Nicol GE. Psychedelic Drug legislative reform and legalization in the US. JAMA Psychiarty. 2023;80:77–83. doi:10.1001/jamapsychiatry.2022.4101.
   PubMed Web of Science ®Google Scholar
• Authority OH. Psilocybin 101: what to know about Oregon’s psilocybin services. Blog OHN, editor. State of Oregon Government; 2023. https://covidblog.oregon.gov/psilocybin-101-what-to-know-about-oregons-psilocybin-services/.
   Google Scholar
• Cada C. Colorado decriminalized psilocybin. Here’s your guided trip through what happens next. The Colorado Sun. 2023.
   Google Scholar
• Haagen JF, Smid GE, Knipscheer JW, Kleber RJ. The efficacy of recommended treatments for veterans with PTSD: a metaregression analysis. Clin Psychol Rev. 2015;40:184–94. doi:10.1016/j.cpr.2015.06.008.
   PubMed Web of Science ®Google Scholar
• Reisman M. PTSD treatment for veterans: what’s working, what’s new, and what’s next. Pharmacy and Therapeutics. 2016;41:623–34.
   Google Scholar
• Eftekhari A, Ruzek JI, Crowley JJ, Rosen CS, Greenbaum MA, Karlin BE. Effectiveness of national implementation of prolonged exposure therapy in veterans Affairs care. JAMA Psychiarty. 2013;70:949–55. doi:10.1001/jamapsychiatry.2013.36.
   PubMed Web of Science ®Google Scholar
• Rauch SA, Kim HM, Powell C, Tuerk PW, Simon NM, Acierno R, Allard CB, et al. Efficacy of prolonged exposure therapy, sertraline hydrochloride, and their combination among combat veterans with posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiarty. 2019;76:117–26. doi:10.1001/jamapsychiatry.2018.3412.
   PubMed Web of Science ®Google Scholar
• Vergun D. Officials describe special operations forces’ contributions to national security. U.S. Department of Defense; 2021. https://www.defense.gov/News/News-Stories/Article/Article/2550459/officials-describe-special-operations-forces-contributions-to-national-security/.
   Google Scholar
• Hing M, Cabrera J, Barstow C, Forsten R. Special operations forces and incidence of post-traumatic stress disorder symptoms. J Spec Oper Med. 2012;12:23–35. doi:10.55460/663M-6L7P.
   PubMedGoogle Scholar
• SOAA. Study reveals SOF suicides highest in military. 2020. https://soaa.org/study-sof-suicides-military/.
   Google Scholar
• Turse NUS. Commandos at risk for suicide: is the military doing enough? The New York Times Magazine. 2020.
   Google Scholar
• Garcia A, Kretzmer TS, Dams-O’Connor K, Miles SR, Bajor L, Tang X, Belanger HG, Merritt BP, Eapen B, McKenzie-Hartman T, et al. Health conditions among special operations forces versus conventional military service members: a VA TBI Model Systems study. J Head Trauma Rehabil. 2022;37:E292–E8. doi:10.1097/HTR.0000000000000737.
   PubMed Web of Science ®Google Scholar
• Campbell-Sills L, Stein MB, Liu H, Agtarap S, Heeringa SG, Nock MK, Ursano RJ, Kessler RC. Associations of Lifetime traumatic Brain Injury Characteristics with Prospective suicide Attempt among Deployed US Army Soldiers. J Head Trauma Rehabil. 2020;35:14–26. doi:10.1097/HTR.0000000000000516.
   PubMed Web of Science ®Google Scholar
• Armstrong SB, Xin Y, Sepeda ND, Polanco M, Averill LA, Davis AK. Prospective associations of psychedelic treatment for co-occurring alcohol misuse and posttraumatic stress symptoms among United States special operations forces veterans. Mil Psychol. 2023;1–8. doi:10.1080/08995605.2022.2156200.
   Web of Science ®Google Scholar
• Davis AK, Averill LA, Sepeda ND, Barsuglia JP, Amoroso T. Psychedelic treatment for trauma-related psychological and cognitive impairment among US special operations forces veterans. Chronic Stress. 2020;4:2470547020939564. doi:10.1177/2470547020939564.
   Google Scholar
• Mangini P, Averill LA, Davis AK. Psychedelic treatment for co-occurring alcohol misuse and post-traumatic stress symptoms among United States special operations forces veterans. J Psychedelic Stud. 2022;5:149–55. doi:10.1556/2054.2021.00176.
   Google Scholar
• Davis AK, Xin Y, Sepeda ND, and Averill LA. “Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: Prospective data from a clinical program in Mexico.” The American Journal of Drug and Alcohol Abuse. 2023. 10.1080/00952990.2023.2220874.
   Web of Science ®Google Scholar
• Rucker J, Seynaeve M, Young AH, Roberts C, Suttle B, Yamamoto T, Ermakova AO, Dunbar F, Wiegand F. 105. Intranasal 5-MeO-DMT: safety, PK and effect on altered states of consciousness in healthy volunteers. Biological Psychiatry. 2023;93:S136. doi:10.1016/j.biopsych.2023.02.345.
   Web of Science ®Google Scholar
• Litjens RP, Brunt TM. How toxic is ibogaine? Clin Toxicol. 2016;54:297–302. doi:10.3109/15563650.2016.1138226.
   PubMed Web of Science ®Google Scholar
• Knuijver T, Schellekens A, Belgers M, Donders R, van Oosteren T, Kramers K, Verkes R. Safety of ibogaine administration in detoxification of opioid‐dependent individuals: a descriptive open‐label observational study. Addiction. 2022;117:118–28. doi:10.1111/add.15448.
   PubMed Web of Science ®Google Scholar
• Barsuglia JP, Polanco M, Palmer R, Malcolm BJ, Kelmendi B, Calvey T. A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder. Prog Brain Res. 2018;242:121–58.
   PubMed Web of Science ®Google Scholar
• Hartogsohn I. Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology. J Psychopharmacol. 2016;30:1259–67. doi:10.1177/0269881116677852.
   PubMed Web of Science ®Google Scholar